$君实生物-U(SH688180)$ ，$科兴制药(SH688136)$
吉利德GS-5245（瑞德西韦的前药变体）在22年1月底启动，目前处在P1阶段。
总算动了，吉列德不动我一直担心这条路线有问题，就看抢速度了。
报道网址：网页链接
Gilead is developing its own oral drug—a remdesivir prodrug dubbed GS-5245—which can quickly turn into remdesivir inside the body. A phase 1 trial of the drug is now underway, O’Day said in a Friday statement. A previous study found a prodrug of remdesivir was effective at neutralizing coronavirus in ferrets, blocking virus replication and preventing transmission to other animals.
Speaking to oral remdesivir’s potential competition with Paxlovid, Gilead Chief Medical Officer Merdad Parsey, M.D., Ph.D., said combination therapies could be the future of COVID-19 treatment to combat potential drug resistance. Paxlovid includes a protease inhibitor, which targets an enzyme key in viral replication before RNA replication.
“We’re going to need multiple mechanisms out there to be able to treat [COVID-19] outpatients,” Parsey said during a JPM presentation. “We really think it’s an ‘and,’ not an ‘or.’”